CHALLENGING ASTHMA MANAGEMENT WITH THE USE OF LABA/ICS COMBINATION VIA A TURBUHALER DEVICE, BOTH FOR MAINTENANCE AS WELL AS RELIEF, AND IT'S INFLUENCE ON ASTHMA CONTROL AND PATIENTS' WELL-BEING IN GREECE
Author(s)
Leonidas Kostagiolas, BSc, MSc, MBM, Health Economics and Outcomes Research Specialist1, Antonios Rasidakis, MD, Assistant Professor2, Gregory Daskos, MD, Head of Medical Affairs and Health Economics11AstraZeneca SA, Athens, Greece; 2 Metropolitan Hospital, Athens, Greece
OBJECTIVES: Current asthma treatments according to GINA 2007 guidelines have been designed to offer a better asthma control and thereby optimal patient well-being. This study aims to demonstrate their impact on a Greek asthmatic population. METHODS: A total of 747 patients were included in the study. 614 were included in the analysis (261 males / 353 females, mean age 49 / 46 years). They were visiting their primary care physician (52% general practitioners, 48% specialists) for their asthma. All patients had moderate to severe asthma and were treated with a LABA/ICS combination, both for maintenance and relief (budesonide/formoterol via Turbuhaler® according to the approved dosage), according to current clinical practice for at least one month prior to their enrollment. They completed a package of questionnaires; the Asthma Control Questionnaire (ACQ), the Asthma Quality of Life Questionnaire (AQLQ), and questions on treatment satisfaction. RESULTS: Eighty-five percent of the patients perceived their asthma as controlled. Of these patients, 67% were well controlled or partly controlled (WCoPC) (ACQ
Conference/Value in Health Info
2008-11, ISPOR Europe 2008, Athens, Greece
Value in Health, Vol. 11, No. 6 (November 2008)
Code
PRS35
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes, Stated Preference & Patient Satisfaction
Disease
Respiratory-Related Disorders